An expansion of TIGIT+KLRG1+ (double positive; DP) CD8+ T cells, described as partially exhausted, was linked to good clinical outcome in trials of anti-CD3 mAb teplizumab in RO and at-risk subjects in T1D (22). This evidence concerns the gene CD8A and type 1 diabetes mellitus.